www.praktickelekarenstvi.cz e37 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Současná farmakoterapie benigní hyperplazie prostaty dle doporučení EAU The Bladder. Int Neurourol J, 2017; 21: 6. https://www.ncbi.nlm.nih.gov/pubmed/28361520. 35. Liao CH, et al. Mirabegron 25mg Monotherapy Is Safe but Less Effective in Male Pati‑ ents With Overactive Bladder and Bladder Outlet Obstruction. Urology 2018; 117: 115. htt‑ ps://www.ncbi.nlm.nih.gov/pubmed/29630956. 36. Van Gelderen M, et al. Absence of clinically relevant cardiovascular interaction upon ad‑ d-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middleagedm to elderly men. International Journal of Clinical Pharmacology and Therapeutics 2014; 52: 693. https://www.ncbi.nlm.nih.gov/pubmed/24755125. 37. Athanasopoulos A, et al. Combination treatment with an alpha-blocker plus an anti‑ cholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253. https://www.ncbi.nlm.nih.gov/pubmed/12771763. 38. Roehrborn CG, et al. Efficacy and safety of a fixed-dose combination of dutasteride And tamsulosin treatment (Duodart((R)) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign pro‑ static hyperplasia: 2-year CONDUCT study results. BJU Int 2015; 116: 450.https://www.ncbi. nlm.nih.gov/pubmed/25565364. 39. Roehrborn CG, et al. Influence of baseline variables on changes in International Pro‑ state Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy In patients with benign prostatic hyperplasia and lower urinary tract symp‑ toms: 4-year results of The CombAT study. BJU Int 2014; 113: 623. https://www.ncbi.nlm. nih.gov/pubmed/24127818. 40. Kaplan SA, et al. Time Course of Incident Adverse Experiences Associated with Doxa‑ zosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. J Urol 2016; 195: 1825. https://www.ncbi.nlm.nih.gov/pubmed/26678956. 41. Lee HN, et al. Rate and associated factors of solifenacin add-on after tamsulosin Mo‑ notherapy in men with voiding and storage lower urinary tract symptoms. International Journal of Clinical Practice 2015; 69: 444. https://www.ncbi.nlm.nih.gov/pubmed/25363606. 42. Van Kerrebroeck P, et al. Combination therapy with solifenacin and tamsulosin oral Con‑ trolled absorption system in a single tablet for lower urinary tract symptoms in men: effi‑ cacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 2013; 64: 1003. https://www.ncbi.nlm.nih.gov/pubmed/23932438. 43. Athanasopoulos A, et al. The role of antimuscarinics in the management of men with Symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011; 60: 94. https://www.ncbi.nlm.nih.gov/pubmed/21497434. 44. Kaplan SA, et al. Antimuscarinics for treatment of storage lower urinary tract symp‑ toms in men: a systematic review. Int J Clin Pract 2011; 65: 487. https://www.ncbi.nlm.nih. gov/pubmed/21210910. 45. Kim HJ, et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker With an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Uri‑ nary Tract Symptoms: Updated Meta-Analysis. PLoS One 2017; 12: e0169248. https://www. ncbi.nlm.nih.gov/pubmed/28072862. 46. Drake MJ, et al. Long-term safety and efficacy of single-tablet combinations of solife‑ nacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE study and NEPTUNE II open‑ -label extension. Eur Urol 2015. 67: 262. https://www.ncbi.nlm.nih.gov/pubmed/25070148. 47. Drake MJ, et al. Responder and health-related quality of life analyses in men with L ower Urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsu‑ losin OCAS: results from the NEPTUNE study. BJU Int 2016; 117: 165. https://www.ncbi.nlm. nih.gov/pubmed/25907003. 48. Gong M, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin 2015; 31: 1781. https://www.ncbi.nlm.nih.gov/pubmed/26211817. 49. Kaplan SA, et al. Solifenacin plus tamsulosin combination treatment inmen with lower uri‑ nary Tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 2013. 63: 158. https://www.ncbi.nlm.nih.gov/pubmed/22831853. 50. Stárka L, Sosvorová L, Mikšátková P. Herbální přípravky používané při léčbě příznaků benigní hyperplazie prostaty. Urol. praxi 2012; 13(6): 244–246. 51. Madersbacher S, et al. Plant extracts: sense or nonsense? Curr Opin Urol 2008; 18: 16. https://www.ncbi.nlm.nih.gov/pubmed/18090484. 52. Kliment J, Horňák M, et al. Peparáty z rastlinných extraktov, In: Kliment J, Horňák M, et al. Benígna hyperplázia prostaty. Osveta, Martin 1996: 167–170. ISBN: 80-217-0343-1. 53. De Monte C, et al. Modern extraction techniques and their impact on the pharmaco‑ logical profile of Serenoa repens extracts for the treatment of lower urinary tract symp‑ toms. BMC Urol 2014; 14: 63. https://www.ncbi.nlm.nih.gov/pubmed/25112532. 54. Slíva J. Serenoa repens v léčbě benigní hyperplazie prostaty. Urol. praxi 2017; 18(4): 165–168. 55. Vávřová L. Účinky hexanového extraktu z palmy pilovité (Serenoa repens, Permixon® 160 mg, v ČR dostupný pod názvem Capistan®) na zánětlivé biomarkery v léčbě obtíží sou‑ visejících s benigní hyperplazií prostaty. Urol. praxi 2016; 17(4): 192–194. 56. EuropeanMedicines Agency Committee on Herbal Medicinal Products. European Union Herbal monograph on Serenoa repens (W. Bartram) Small, fructus. EMA/HMPC/280079/2013, 2015. https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-uni‑ on-herbalmonograph-serenoa-repens-w-bartram-small-fructus_en.pdf.
RkJQdWJsaXNoZXIy NDA4Mjc=